| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $32.2M | +16.0% | +60.1% |
| SG&A Expense | $6.1M | +4.2% | +48.4% |
| Operating Income | -$38.3M | -14.0% | -58.1% |
| Net Income | -$35.0M | -11.4% | -70.1% |
| EPS (Basic) | -$0.83 | +7.8% | -36.1% |
| EPS (Diluted) | -$0.83 | +7.8% | -36.1% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $112.7M | -0.1% | -60.2% |
| Short-term Investments | $187.6M | +52.6% | — |
| Current Assets | $321.2M | +28.4% | +9.9% |
| Total Assets | $326.6M | +21.2% | +11.6% |
| Current Liabilities | $21.6M | +9.8% | +42.2% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$129.9M | — | — |
| Investing Cash Flow | -$29K | — | — |
| Financing Cash Flow | $168.3M | — | — |
| $21.6M |
| +9.8% |
| +41.7% |
| Stockholders' Equity | $305.0M | +22.1% | +9.9% |